Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

作者：Moti Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Díaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Sharon Walmsley, James J. Sims, Giovanni Di Perri, Kenneth Sutton, Denise Sutherland‐Phillips, Alessandro Berni, Christine L. Latham, Feifan Zhang, Ronald D’Amico, Miguel Pascual Bernáldez, Rodica Van Solingen‐Ristea, Veerle Van Eygen, Parul Patel, Vasiliki Chounta, William Spreen, H Garges, Kimberly Y. Smith, Jean van Wyk · 发表于：The Lancet HIV · 年份：2023 · DOI：10.1016/s2352-3018(23)00136-4 · 被引用次数：118 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV-related health complications and treatments